"Netrin-slaying nanoparticles: A new frontier in cancer therapy" Article Swipe
Vishakha Sherawat
,
Deepika Sharma
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.bbadva.2025.100163
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.bbadva.2025.100163
Netrin-1, a secreted laminin-related protein, was first characterized for its pivotal role in guiding axonal growth during nervous system development. However, recent research has revealed its involvement in cancer progression and metastasis. Understanding the signaling pathways through which Netrin-1 operates in cancer is crucial for elucidating its mechanisms and exploring therapeutic interventions. Netrin-1 protein controls the biological processes of cancer cells, guiding axon pathfinding and transmitting signals that are essential for migration, differentiation and cell survival via UNC5 and DCC-family receptors. To elaborate further, Netrin1 controls YAP signalling through its neogenin receptor, which affects the EMT process in gastric cancer. Researchers have also utilized the Netrin-1 protein with different nanoparticles to explore its way to prevent cancer progression. Moreover, Researchers evaluated the use of nanoparticles as an immunosensor, therapeutic and imaging tools targetting the Netrin-1 protein, which open several ways to combat cancer. This review explores how Netrin-1 influences the AKT signaling cascade impacting hippo signaling, YAP pathways and EMT process with DCC receptor. It also discusses the involvement of UNC5B and Netrin-1 in regulating ERK/MAPK signaling pathways and induction of apoptosis when Netrin-1 is absent. Moreover, it underscores the therapeutic potential of UNC5B-induced cell cycle arrest in specific cancer. Also, it delves into the diverse forms of netrin and its potential role in cancer and the glims of nanoparticles use with it. Underlining the necessity for more research to comprehend their functions in signaling cascades using the nanomaterials.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.bbadva.2025.100163
- OA Status
- gold
- References
- 91
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411177203
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411177203Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.bbadva.2025.100163Digital Object Identifier
- Title
-
"Netrin-slaying nanoparticles: A new frontier in cancer therapy"Work title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-01-01Full publication date if available
- Authors
-
Vishakha Sherawat, Deepika SharmaList of authors in order
- Landing page
-
https://doi.org/10.1016/j.bbadva.2025.100163Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.bbadva.2025.100163Direct OA link when available
- Concepts
-
Frontier, Netrin, Cancer therapy, Cancer, Nanoparticle, Medicine, Cancer research, Nanotechnology, Internal medicine, Materials science, Receptor, History, Archaeology, Axon guidanceTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
91Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411177203 |
|---|---|
| doi | https://doi.org/10.1016/j.bbadva.2025.100163 |
| ids.doi | https://doi.org/10.1016/j.bbadva.2025.100163 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40584519 |
| ids.openalex | https://openalex.org/W4411177203 |
| fwci | 0.0 |
| type | review |
| title | "Netrin-slaying nanoparticles: A new frontier in cancer therapy" |
| awards[0].id | https://openalex.org/G5840532195 |
| awards[0].funder_id | https://openalex.org/F4320320720 |
| awards[0].display_name | |
| awards[0].funder_award_id | IIRPSG-2024\u201301\u201305022 |
| awards[0].funder_display_name | Indian Council of Medical Research |
| biblio.issue | |
| biblio.volume | 8 |
| biblio.last_page | 100163 |
| biblio.first_page | 100163 |
| topics[0].id | https://openalex.org/T12061 |
| topics[0].field.id | https://openalex.org/fields/28 |
| topics[0].field.display_name | Neuroscience |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2804 |
| topics[0].subfield.display_name | Cellular and Molecular Neuroscience |
| topics[0].display_name | Axon Guidance and Neuronal Signaling |
| topics[1].id | https://openalex.org/T10492 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9904999732971191 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1307 |
| topics[1].subfield.display_name | Cell Biology |
| topics[1].display_name | Microtubule and mitosis dynamics |
| topics[2].id | https://openalex.org/T13779 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9855999946594238 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Cancer Mechanisms and Therapy |
| funders[0].id | https://openalex.org/F4320320720 |
| funders[0].ror | https://ror.org/0492wrx28 |
| funders[0].display_name | Indian Council of Medical Research |
| is_xpac | False |
| apc_list.value | 2300 |
| apc_list.currency | USD |
| apc_list.value_usd | 2300 |
| apc_paid.value | 2300 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2300 |
| concepts[0].id | https://openalex.org/C2778571376 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7343865633010864 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1355821 |
| concepts[0].display_name | Frontier |
| concepts[1].id | https://openalex.org/C127955056 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6093727350234985 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q83133937 |
| concepts[1].display_name | Netrin |
| concepts[2].id | https://openalex.org/C2983331546 |
| concepts[2].level | 3 |
| concepts[2].score | 0.5268995761871338 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[2].display_name | Cancer therapy |
| concepts[3].id | https://openalex.org/C121608353 |
| concepts[3].level | 2 |
| concepts[3].score | 0.501542329788208 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[3].display_name | Cancer |
| concepts[4].id | https://openalex.org/C155672457 |
| concepts[4].level | 2 |
| concepts[4].score | 0.48205551505088806 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q61231 |
| concepts[4].display_name | Nanoparticle |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.44052448868751526 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C502942594 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3382861018180847 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[6].display_name | Cancer research |
| concepts[7].id | https://openalex.org/C171250308 |
| concepts[7].level | 1 |
| concepts[7].score | 0.2978072762489319 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11468 |
| concepts[7].display_name | Nanotechnology |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.24196767807006836 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C192562407 |
| concepts[9].level | 0 |
| concepts[9].score | 0.15301594138145447 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q228736 |
| concepts[9].display_name | Materials science |
| concepts[10].id | https://openalex.org/C170493617 |
| concepts[10].level | 2 |
| concepts[10].score | 0.12367787957191467 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[10].display_name | Receptor |
| concepts[11].id | https://openalex.org/C95457728 |
| concepts[11].level | 0 |
| concepts[11].score | 0.11225074529647827 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q309 |
| concepts[11].display_name | History |
| concepts[12].id | https://openalex.org/C166957645 |
| concepts[12].level | 1 |
| concepts[12].score | 0.059876441955566406 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q23498 |
| concepts[12].display_name | Archaeology |
| concepts[13].id | https://openalex.org/C69125201 |
| concepts[13].level | 3 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q2034716 |
| concepts[13].display_name | Axon guidance |
| keywords[0].id | https://openalex.org/keywords/frontier |
| keywords[0].score | 0.7343865633010864 |
| keywords[0].display_name | Frontier |
| keywords[1].id | https://openalex.org/keywords/netrin |
| keywords[1].score | 0.6093727350234985 |
| keywords[1].display_name | Netrin |
| keywords[2].id | https://openalex.org/keywords/cancer-therapy |
| keywords[2].score | 0.5268995761871338 |
| keywords[2].display_name | Cancer therapy |
| keywords[3].id | https://openalex.org/keywords/cancer |
| keywords[3].score | 0.501542329788208 |
| keywords[3].display_name | Cancer |
| keywords[4].id | https://openalex.org/keywords/nanoparticle |
| keywords[4].score | 0.48205551505088806 |
| keywords[4].display_name | Nanoparticle |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.44052448868751526 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/cancer-research |
| keywords[6].score | 0.3382861018180847 |
| keywords[6].display_name | Cancer research |
| keywords[7].id | https://openalex.org/keywords/nanotechnology |
| keywords[7].score | 0.2978072762489319 |
| keywords[7].display_name | Nanotechnology |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.24196767807006836 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/materials-science |
| keywords[9].score | 0.15301594138145447 |
| keywords[9].display_name | Materials science |
| keywords[10].id | https://openalex.org/keywords/receptor |
| keywords[10].score | 0.12367787957191467 |
| keywords[10].display_name | Receptor |
| keywords[11].id | https://openalex.org/keywords/history |
| keywords[11].score | 0.11225074529647827 |
| keywords[11].display_name | History |
| keywords[12].id | https://openalex.org/keywords/archaeology |
| keywords[12].score | 0.059876441955566406 |
| keywords[12].display_name | Archaeology |
| language | en |
| locations[0].id | doi:10.1016/j.bbadva.2025.100163 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210216961 |
| locations[0].source.issn | 2667-1603 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2667-1603 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | BBA Advances |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | BBA Advances |
| locations[0].landing_page_url | https://doi.org/10.1016/j.bbadva.2025.100163 |
| locations[1].id | pmid:40584519 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | BBA advances |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40584519 |
| locations[2].id | pmh:oai:europepmc.org:11013202 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12206008 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5118116259 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Vishakha Sherawat |
| authorships[0].affiliations[0].raw_affiliation_string | Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, India. |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Vishakha Sherawat |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, India. |
| authorships[1].author.id | https://openalex.org/A5100664109 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-6641-173X |
| authorships[1].author.display_name | Deepika Sharma |
| authorships[1].affiliations[0].raw_affiliation_string | Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, India. |
| authorships[1].author_position | last |
| authorships[1].raw_author_name | Deepika Sharma |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, India. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.bbadva.2025.100163 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | "Netrin-slaying nanoparticles: A new frontier in cancer therapy" |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12061 |
| primary_topic.field.id | https://openalex.org/fields/28 |
| primary_topic.field.display_name | Neuroscience |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2804 |
| primary_topic.subfield.display_name | Cellular and Molecular Neuroscience |
| primary_topic.display_name | Axon Guidance and Neuronal Signaling |
| related_works | https://openalex.org/W2045172642, https://openalex.org/W2026040351, https://openalex.org/W1981143054, https://openalex.org/W1971482781, https://openalex.org/W2117924558, https://openalex.org/W2124440591, https://openalex.org/W2046422583, https://openalex.org/W2100166053, https://openalex.org/W1543519398, https://openalex.org/W2169328446 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1016/j.bbadva.2025.100163 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210216961 |
| best_oa_location.source.issn | 2667-1603 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2667-1603 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | BBA Advances |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | BBA Advances |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.bbadva.2025.100163 |
| primary_location.id | doi:10.1016/j.bbadva.2025.100163 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210216961 |
| primary_location.source.issn | 2667-1603 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2667-1603 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | BBA Advances |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | BBA Advances |
| primary_location.landing_page_url | https://doi.org/10.1016/j.bbadva.2025.100163 |
| publication_date | 2025-01-01 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2030694827, https://openalex.org/W6645146600, https://openalex.org/W2133683998, https://openalex.org/W3157300421, https://openalex.org/W784992116, https://openalex.org/W4376128416, https://openalex.org/W2113605797, https://openalex.org/W2104620926, https://openalex.org/W6675324302, https://openalex.org/W2256754589, https://openalex.org/W2123283055, https://openalex.org/W4323295147, https://openalex.org/W1995880664, https://openalex.org/W2007739207, https://openalex.org/W2062276405, https://openalex.org/W2145027672, https://openalex.org/W2020904729, https://openalex.org/W4395663198, https://openalex.org/W4385490780, https://openalex.org/W3190572669, https://openalex.org/W2154139219, https://openalex.org/W3138885095, https://openalex.org/W4309506674, https://openalex.org/W2102281174, https://openalex.org/W2046422583, https://openalex.org/W1968422847, https://openalex.org/W2026812650, https://openalex.org/W2074557008, https://openalex.org/W4310725368, https://openalex.org/W2606157727, https://openalex.org/W2156775517, https://openalex.org/W2001455128, https://openalex.org/W2090587506, https://openalex.org/W2071958906, https://openalex.org/W2022081467, https://openalex.org/W2121764727, https://openalex.org/W2044161694, https://openalex.org/W2029920356, https://openalex.org/W3122008734, https://openalex.org/W2048888260, https://openalex.org/W2158172740, https://openalex.org/W4391721620, https://openalex.org/W4391897157, https://openalex.org/W4391814025, https://openalex.org/W6785621338, https://openalex.org/W3001101087, https://openalex.org/W2101832470, https://openalex.org/W3029460702, https://openalex.org/W2790470634, https://openalex.org/W6758578187, https://openalex.org/W3012807061, https://openalex.org/W3096940579, https://openalex.org/W2889131486, https://openalex.org/W3190288797, https://openalex.org/W3137026955, https://openalex.org/W2736147667, https://openalex.org/W2903441014, https://openalex.org/W2554241644, https://openalex.org/W2806049536, https://openalex.org/W2792860038, https://openalex.org/W2611330723, https://openalex.org/W2534609774, https://openalex.org/W1853713845, https://openalex.org/W3216309600, https://openalex.org/W2993233611, https://openalex.org/W2887611313, https://openalex.org/W2781675089, https://openalex.org/W2952456277, https://openalex.org/W2893545736, https://openalex.org/W6747933373, https://openalex.org/W3009320963, https://openalex.org/W6775140748, https://openalex.org/W2967245975, https://openalex.org/W3187957129, https://openalex.org/W4300082209, https://openalex.org/W2095100212, https://openalex.org/W4385490576, https://openalex.org/W3165586952, https://openalex.org/W3081675040, https://openalex.org/W2042323932, https://openalex.org/W2149441684, https://openalex.org/W3022334388, https://openalex.org/W6753567552, https://openalex.org/W2053374578, https://openalex.org/W2784310020, https://openalex.org/W4233120011, https://openalex.org/W2911271053, https://openalex.org/W3105824585, https://openalex.org/W2398350456, https://openalex.org/W2885798069, https://openalex.org/W1979522770 |
| referenced_works_count | 91 |
| abstract_inverted_index.a | 1 |
| abstract_inverted_index.It | 164 |
| abstract_inverted_index.To | 81 |
| abstract_inverted_index.an | 126 |
| abstract_inverted_index.as | 125 |
| abstract_inverted_index.in | 12, 27, 40, 97, 173, 197, 213, 233 |
| abstract_inverted_index.is | 42, 184 |
| abstract_inverted_index.it | 187, 201 |
| abstract_inverted_index.of | 58, 123, 169, 180, 192, 207, 218 |
| abstract_inverted_index.to | 110, 114, 140, 229 |
| abstract_inverted_index.AKT | 150 |
| abstract_inverted_index.DCC | 162 |
| abstract_inverted_index.EMT | 95, 159 |
| abstract_inverted_index.YAP | 86, 156 |
| abstract_inverted_index.and | 30, 48, 64, 73, 78, 129, 158, 171, 178, 209, 215 |
| abstract_inverted_index.are | 68 |
| abstract_inverted_index.for | 8, 44, 70, 226 |
| abstract_inverted_index.has | 23 |
| abstract_inverted_index.how | 146 |
| abstract_inverted_index.it. | 222 |
| abstract_inverted_index.its | 9, 25, 46, 89, 112, 210 |
| abstract_inverted_index.the | 33, 55, 94, 104, 121, 133, 149, 167, 189, 204, 216, 224, 237 |
| abstract_inverted_index.use | 122, 220 |
| abstract_inverted_index.via | 76 |
| abstract_inverted_index.was | 5 |
| abstract_inverted_index.way | 113 |
| abstract_inverted_index.This | 143 |
| abstract_inverted_index.UNC5 | 77 |
| abstract_inverted_index.also | 102, 165 |
| abstract_inverted_index.axon | 62 |
| abstract_inverted_index.cell | 74, 194 |
| abstract_inverted_index.have | 101 |
| abstract_inverted_index.into | 203 |
| abstract_inverted_index.more | 227 |
| abstract_inverted_index.open | 137 |
| abstract_inverted_index.role | 11, 212 |
| abstract_inverted_index.that | 67 |
| abstract_inverted_index.ways | 139 |
| abstract_inverted_index.when | 182 |
| abstract_inverted_index.with | 107, 161, 221 |
| abstract_inverted_index.Also, | 200 |
| abstract_inverted_index.UNC5B | 170 |
| abstract_inverted_index.cycle | 195 |
| abstract_inverted_index.first | 6 |
| abstract_inverted_index.forms | 206 |
| abstract_inverted_index.glims | 217 |
| abstract_inverted_index.hippo | 154 |
| abstract_inverted_index.their | 231 |
| abstract_inverted_index.tools | 131 |
| abstract_inverted_index.using | 236 |
| abstract_inverted_index.which | 37, 92, 136 |
| abstract_inverted_index.arrest | 196 |
| abstract_inverted_index.axonal | 14 |
| abstract_inverted_index.cancer | 28, 41, 59, 116, 214 |
| abstract_inverted_index.cells, | 60 |
| abstract_inverted_index.combat | 141 |
| abstract_inverted_index.delves | 202 |
| abstract_inverted_index.during | 16 |
| abstract_inverted_index.growth | 15 |
| abstract_inverted_index.netrin | 208 |
| abstract_inverted_index.recent | 21 |
| abstract_inverted_index.review | 144 |
| abstract_inverted_index.system | 18 |
| abstract_inverted_index.Netrin1 | 84 |
| abstract_inverted_index.absent. | 185 |
| abstract_inverted_index.affects | 93 |
| abstract_inverted_index.cancer. | 99, 142, 199 |
| abstract_inverted_index.cascade | 152 |
| abstract_inverted_index.crucial | 43 |
| abstract_inverted_index.diverse | 205 |
| abstract_inverted_index.explore | 111 |
| abstract_inverted_index.gastric | 98 |
| abstract_inverted_index.guiding | 13, 61 |
| abstract_inverted_index.imaging | 130 |
| abstract_inverted_index.nervous | 17 |
| abstract_inverted_index.pivotal | 10 |
| abstract_inverted_index.prevent | 115 |
| abstract_inverted_index.process | 96, 160 |
| abstract_inverted_index.protein | 53, 106 |
| abstract_inverted_index.several | 138 |
| abstract_inverted_index.signals | 66 |
| abstract_inverted_index.through | 36, 88 |
| abstract_inverted_index.ERK/MAPK | 175 |
| abstract_inverted_index.However, | 20 |
| abstract_inverted_index.Netrin-1 | 38, 52, 105, 134, 147, 172, 183 |
| abstract_inverted_index.cascades | 235 |
| abstract_inverted_index.controls | 54, 85 |
| abstract_inverted_index.explores | 145 |
| abstract_inverted_index.further, | 83 |
| abstract_inverted_index.neogenin | 90 |
| abstract_inverted_index.operates | 39 |
| abstract_inverted_index.pathways | 35, 157, 177 |
| abstract_inverted_index.protein, | 4, 135 |
| abstract_inverted_index.research | 22, 228 |
| abstract_inverted_index.revealed | 24 |
| abstract_inverted_index.secreted | 2 |
| abstract_inverted_index.specific | 198 |
| abstract_inverted_index.survival | 75 |
| abstract_inverted_index.utilized | 103 |
| abstract_inverted_index.Moreover, | 118, 186 |
| abstract_inverted_index.Netrin-1, | 0 |
| abstract_inverted_index.apoptosis | 181 |
| abstract_inverted_index.different | 108 |
| abstract_inverted_index.discusses | 166 |
| abstract_inverted_index.elaborate | 82 |
| abstract_inverted_index.essential | 69 |
| abstract_inverted_index.evaluated | 120 |
| abstract_inverted_index.exploring | 49 |
| abstract_inverted_index.functions | 232 |
| abstract_inverted_index.impacting | 153 |
| abstract_inverted_index.induction | 179 |
| abstract_inverted_index.necessity | 225 |
| abstract_inverted_index.potential | 191, 211 |
| abstract_inverted_index.processes | 57 |
| abstract_inverted_index.receptor, | 91 |
| abstract_inverted_index.receptor. | 163 |
| abstract_inverted_index.signaling | 34, 151, 176, 234 |
| abstract_inverted_index.DCC-family | 79 |
| abstract_inverted_index.biological | 56 |
| abstract_inverted_index.comprehend | 230 |
| abstract_inverted_index.influences | 148 |
| abstract_inverted_index.mechanisms | 47 |
| abstract_inverted_index.migration, | 71 |
| abstract_inverted_index.receptors. | 80 |
| abstract_inverted_index.regulating | 174 |
| abstract_inverted_index.signaling, | 155 |
| abstract_inverted_index.signalling | 87 |
| abstract_inverted_index.targetting | 132 |
| abstract_inverted_index.Researchers | 100, 119 |
| abstract_inverted_index.Underlining | 223 |
| abstract_inverted_index.elucidating | 45 |
| abstract_inverted_index.involvement | 26, 168 |
| abstract_inverted_index.metastasis. | 31 |
| abstract_inverted_index.pathfinding | 63 |
| abstract_inverted_index.progression | 29 |
| abstract_inverted_index.therapeutic | 50, 128, 190 |
| abstract_inverted_index.underscores | 188 |
| abstract_inverted_index.development. | 19 |
| abstract_inverted_index.progression. | 117 |
| abstract_inverted_index.transmitting | 65 |
| abstract_inverted_index.UNC5B-induced | 193 |
| abstract_inverted_index.Understanding | 32 |
| abstract_inverted_index.characterized | 7 |
| abstract_inverted_index.immunosensor, | 127 |
| abstract_inverted_index.nanoparticles | 109, 124, 219 |
| abstract_inverted_index.interventions. | 51 |
| abstract_inverted_index.nanomaterials. | 238 |
| abstract_inverted_index.differentiation | 72 |
| abstract_inverted_index.laminin-related | 3 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 2 |
| citation_normalized_percentile.value | 0.24466187 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |